Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 9, 2013, Pages 824-832

  Ramcharitar, Jasmine ^a,b   Albrecht, Steffen ^a   Afonso, Veronica M ^a,b   Kaushal, Vikas ^a,b   Bennett, David A ^c,d   Leblanc, Andrea C ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Caspase 6; Cognitive scores; Memory scores; Tau cleaved by caspase 6; Tau Casp6

Indexed keywords

CASPASE 6; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; COGNITION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TASK PERFORMANCE; WORKING MEMORY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; CASPASE 6; CELL LINE, TRANSFORMED; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; POSTMORTEM CHANGES; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; STATISTICS AS TOPIC; TAU PROTEINS; TRANSFECTION;

EID: 84883597550     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182a0a39f     Document Type: Article

References (37)

1. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74
2. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011;29:26-32
3. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25
4. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224-34
5. Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: Pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 2009;1180:28-35
6. Diniz BS, Pinto Júnior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008;9:172-82
7. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-89
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13
9. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187-90
10. Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006; 67:1600-4
11. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-12
12. Albrecht S, Bogdanovic N, Ghetti B, et al. Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations. J Neuropathol Exp Neurol 2009; 68:1282-93
13. Albrecht S, Bourdeau M, Bennett D, et al. Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 2007;170:1200-9
14. Guo H, Albrecht S, Bourdeau M, et al. Active caspase-6 and caspase-6 cleaved Tau in neuropil threads, neuritic plaques and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004;165:523-31
15. Ramcharitar J, Afonso VM, Albrecht S, et al. Caspase-6 activity predicts lower episodic memory ability in aged individuals. Neurobiol Aging 2013;34:1815-24
16. Klaiman G, Petzke TL, Hammond J, et al. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol Cell Proteomics 2008;7:1541-55
17. Nikolaev A, McLaughlin T, O'Leary DD, et al. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457: 981-89
18. Sivananthan SN, Lee AW, Goodyer CG, et al. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid beta-peptideY independent neuronal degeneration in primary human neuron cultures. Cell Death Dis 2010;1:e100
19. Bennett DA, Schneider JA, Buchman AS, et al. Overview and findings from the rush memory and aging project. Curr Alzheimer Res 2012;9: 646-63
20. Wilson RS, Schneider JA, Arnold SE, et al. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry 2007;64:1204-12
21. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64:834-41
22. Mai JK, Paxinos G, Voss T. Atlas of the Human Brain. 3rd Ed. Amsterdam, Netherlands: Elsevier; 2008
23. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease: A primer for practicing pathologists. Arch Pathol Lab Med 1993; 117:132-44
24. Platt MS, McClure S, Clarke R, et al. Postmortem cerebrospinal fluid pleocytosis. Am J Forensic Med Pathol 1989;10:209-12
25. Wyler D, Marty W, Bar W. Correlation between the post-mortem cell content of cerebrospinal fluid and time of death. Int J Legal Med 1994; 106:194-99
26. Wang M, Gamo NJ, Yang Y, et al. Neuronal basis of age-related working memory decline. Nature 2011;476:210-13
27. Cusack CL, Swahari V, Hampton Henley W, et al. Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning. Nat Commun 2013;4:1876
28. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 2004;75:61-71
29. Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003;60:1082-88
30. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006;125:1179-91
31. Uribe V, Wong BK, Graham RK, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet 2012;21:1954-67
32. Waldron-Roby E, Ratovitski T, Wang X, et al. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 2012; 32:183-93
33. Warby SC, Doty CN, Graham RK, et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 2008;17:2390-404
34. Giaime E, Sunyach C, Druon C, et al. Loss of function of DJ-1 triggered by Parkinson's diseaseYassociated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ 2010;17:158-69
35. Robert G, Puissant A, Dufies M, et al. The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. Cell Death Differ 2012;19:1769-78
36. Gafni J, Papanikolaou T, Degiacomo F, et al. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci 2012;32:7454-65
37. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97